Developer docs
API playgroundTry for free, no card

Search company profiles

reMYND

Full company profile

uuid0000zbv

Namestring
reMYND
Legal namestring
remynd NV
Websiteurl
remynd.com
Company typeenum
Private
Founded yearint
2002
Descriptiontext

reMYND is a Belgian clinical-stage biotechnology company developing first-in-class oral small molecule therapeutics for neurodegenerative diseases, with primary programs in Alzheimer's disease and Huntington's disease. Founded in 2002 and headquartered at the Arenberg Science Park in Leuven (Bio Incubator 3 building), the company employs 11-50 staff and operates as an independent private entity with board representation from Belgian institutional investors including SFPIM, PMV, Korys, and KU Leuven Research & Development.

The company's core technology is a proprietary septin modulation platform, validated by a study published in Science in August 2024. The ReS19-T compound class targets septins — cytoskeletal proteins disrupted in neurodegeneration — acting as molecular glue to restore septin filament integrity and normalize calcium homeostasis in neurons, without affecting healthy cells. Lead clinical-stage assets include REM392 (a second-generation oral septin modulator for Alzheimer's disease, currently in Phase 1) and REM949 (an orally available small molecule with strong brain permeability targeting the neurotoxic effects of mutated huntingtin protein in Huntington's disease, positioned for CTA-enabling studies). A first-generation candidate, REM0046127 (REM127), demonstrated significant memory improvement and biomarker changes in a Phase 2a trial but was terminated due to off-target liver effects, informing the second-generation design. The company also maintains a discovery program targeting mitochondrial dysfunction in ALS.

Historically, reMYND operated a dual model combining proprietary drug development with CRO services that served Top 10 global pharmaceutical companies using its proprietary mouse models. In March 2025, the company divested the CRO business unit to InnoSer to focus exclusively on clinical drug development. As a pre-revenue biotech, reMYND expects future revenue from out-licensing or commercialization of its drug candidates through standard pharmaceutical distribution channels. The company is led by CEO Floor Stam, PhD, and CSO Gerard Griffioen, PhD, and engages the scientific community through publications, conference presentations (including CTAD), and AI partnerships such as its 2025 collaboration with Unlearn on digital twin technology for clinical signal interpretation.

Short descriptiontext

reMYND is a Belgian clinical-stage biotech developing first-in-class oral small molecule therapeutics for Alzheimer's and Huntington's disease using a proprietary septin modulation platform that restores calcium homeostasis in neurons.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersHeverlee, Belgium
HQ citystring
Heverlee
HQ countrystring
Belgium
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
neurodegenerative therapeutics, Alzheimer's drug development, Huntington's disease treatment, small molecule drugs, clinical stage biotech
Industry2 codes
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Neurodegenerative Disease Therapeutics
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Drug Development Programs
TypeOne Time License
Description

Developing proprietary small molecule therapeutics for neurodegenerative diseases (Alzheimer's and Huntington's disease) through clinical stages. Revenue will be generated upon regulatory approval and commercialization of drug candidates.

remynd.com
2CRO Services (Divested)
TypeProfessional Services
Description

Contract Research Organization services providing preclinical testing using proprietary mouse models for neurodegenerative diseases. This business unit was fully integrated into InnoSer in March 2025, ending reMYND's CRO operations.

remynd.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

reMYND develops first-in-class oral small molecule drug candidates targeting neurodegenerative diseases, primarily Alzheimer's and Huntington's disease. The company's proprietary septin modulation platform restores calcium homeostasis in neurons by acting as a molecular glue to repair septin filament integrity. Lead candidates include REM392 (Alzheimer's, Phase 1), REM0046127/REM127 (Alzheimer's, Phase 2a completed), and REM949 (Huntington's, ready for CTA-enabling studies). Following the March 2025 divestiture of its CRO business to InnoSer, reMYND focuses exclusively on advancing these proprietary drug programs through clinical development.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

reMYND is a clinical-stage biotech company developing first-in-class oral treatments for neurodegenerative diseases, particularly Alzheimer's and Huntington's disease. The company's product portfolio centers on septin modulation technology—a novel mechanism targeting cytoskeletal proteins to restore calcium homeostasis in neurons. Lead programs include REM392 (second-generation Alzheimer's candidate in Phase 1), REM127 (first-generation Alzheimer's candidate completing Phase 2a), and REM949 (Huntington's disease candidate entering CTA-enabling studies). The company previously operated a CRO services business which was sold to InnoSer in March 2025, transitioning reMYND to a pure-play drug development organization. Research has been published in Science journal demonstrating the therapeutic potential of septin modulators.

Product and service4 records
1REM392
CategoryAlzheimer's Disease Therapeutics
Description

Second-generation oral small molecule septin modulator for Alzheimer's disease. Restores calcium balance in neurons by targeting septin filaments disrupted by pathological tau. Designed with improved safety profile and pharmacokinetics compared to first-generation candidate REM127. Currently in Phase 1 clinical trials (initiated May 2025).

2REM0046127 (REM127)
CategoryAlzheimer's Disease Therapeutics
Description

First-generation small molecule drug candidate acting as molecular glue to restore septin filament integrity in neurons. Targeted mild-to-moderate Alzheimer's disease patients. Showed significant memory improvement and biomarker changes (p-tau181 reduction, EEG power increase, CSF dopamine increase) in Phase 2a trial. Program was terminated early due to off-target liver effects, leading to development of second-generation candidate REM392.

3REM949
CategoryHuntington's Disease Therapeutics
Description

Lead compound for reMYND's Huntington's disease program. Highly potent, orally available small molecule with excellent brain permeability and promising non-clinical safety and pharmacokinetic properties. Targets neurotoxic effects of mutated huntingtin protein. Ready to enter CTA-enabling studies.

4ReS19-T Compound Class
CategoryNeurodegenerative Disease Drug Platform
Description

Novel class of compounds identified through reMYND's Science publication that restore calcium homeostasis by targeting septins. Showed neuroprotective effects, reduced pathological protein accumulation, and improved memory function in multiple disease models of Alzheimer's. Forms the chemical foundation of reMYND's drug pipeline including REM392 and REM127.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-03-04
Description

Strategic divestiture of reMYND's CRO business unit to InnoSer. The acquisition integrates reMYND's preclinical neuroscience models into InnoSer's neurology platform. This transition allows reMYND to focus exclusively on progressing its clinical drug programs while ensuring continuity of CRO services for global pharma and biotech clients.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Cassava Sciences
TypeDirect peer
Description

Clinical-stage US biotech developing oral small molecules (simufilam) for Alzheimer's disease with a novel mechanism targeting altered protein folding/scaffolding — closely comparable to reMYND in modality (oral small molecule), indication (AD), and disease-modifying ambition.

TypeDirect peer
Description

Clinical-stage biotech developing oral small molecules (blarcamesine) targeting sigma-1 receptor for Alzheimer's and other neurodegenerative diseases. Direct parallel to reMYND as an oral small-molecule CNS company pursuing disease modification.

TypeDirect peer
Description

Clinical-stage biotech developing small molecules and biologics for neurodegenerative diseases (including Parkinson's and ALS) using novel biology-driven approaches. Comparable as a CNS-focused drug developer with multiple programs and strong institutional backing.

TypeDirect peer
Description

Swiss clinical-stage biotech developing both small molecules and immunotherapies targeting misfolded proteins (tau, alpha-synuclein) in Alzheimer's and Parkinson's. Directly comparable to reMYND in targeting protein-misfolding biology in neurodegeneration.

TypeDirect peer
Description

Clinical-stage biotech developing therapeutics for neurodegenerative diseases including Parkinson's, Alzheimer's and ATTR amyloidosis. Comparable as a protein-misfolding-focused CNS biotech with multiple clinical-stage programs.

TypeDirect peer
Description

Clinical-stage biotech developing pridopidine, an oral small molecule for Huntington's disease and ALS. Direct comparable to reMYND on the Huntington's program specifically, sharing oral small-molecule modality and CNS indication.

TypeDirect peer
Description

Clinical-stage biotech developing RNA-targeting therapies for Huntington's disease (and other CNS indications). Direct Huntington's competitor to reMYND's REM949, though differing in modality (antisense oligonucleotides vs. small molecule).

TypeDirect peer
Description

Clinical-stage gene therapy company developing AMT-130 for Huntington's disease. Comparable to reMYND's REM949 as another late-preclinical/early-clinical HD therapeutic, though uniQure uses AAV gene therapy rather than a small molecule.

TypeBroad incumbent
Description

Large biopharmaceutical company with leading Alzheimer's franchise (Leqembi, co-developed with Eisai) and a broader CNS/neurodegeneration pipeline. Comparable as the dominant commercial incumbent in AD that any disease-modifying small molecule like reMYND's would eventually compete against or partner with.

10Eisai
TypeBroad incumbent
Description

Global pharmaceutical company with a major Alzheimer's franchise (Leqembi, Kisunla) and a deep neurodegenerative-disease pipeline. Broad incumbent comparable to reMYND's commercial landscape and a likely potential partner/acquirer for late-stage CNS assets.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

reMYND

Neurodegenerative Disease Therapeuticsremynd.com

reMYND is a Belgian clinical-stage biotech developing first-in-class oral small molecule therapeutics for Alzheimer's and Huntington's disease using a proprietary septin modulation platform that restores calcium homeostasis in neurons.

What reMYND does

reMYND is a Belgian clinical-stage biotechnology company developing first-in-class oral small molecule therapeutics for neurodegenerative diseases, with primary programs in Alzheimer's disease and Huntington's disease. Founded in 2002 and headquartered at the Arenberg Science Park in Leuven (Bio Incubator 3 building), the company employs 11-50 staff and operates as an independent private entity with board representation from Belgian institutional investors including SFPIM, PMV, Korys, and KU Leuven Research & Development.

The company's core technology is a proprietary septin modulation platform, validated by a study published in Science in August 2024. The ReS19-T compound class targets septins — cytoskeletal proteins disrupted in neurodegeneration — acting as molecular glue to restore septin filament integrity and normalize calcium homeostasis in neurons, without affecting healthy cells. Lead clinical-stage assets include REM392 (a second-generation oral septin modulator for Alzheimer's disease, currently in Phase 1) and REM949 (an orally available small molecule with strong brain permeability targeting the neurotoxic effects of mutated huntingtin protein in Huntington's disease, positioned for CTA-enabling studies). A first-generation candidate, REM0046127 (REM127), demonstrated significant memory improvement and biomarker changes in a Phase 2a trial but was terminated due to off-target liver effects, informing the second-generation design. The company also maintains a discovery program targeting mitochondrial dysfunction in ALS.

Historically, reMYND operated a dual model combining proprietary drug development with CRO services that served Top 10 global pharmaceutical companies using its proprietary mouse models. In March 2025, the company divested the CRO business unit to InnoSer to focus exclusively on clinical drug development. As a pre-revenue biotech, reMYND expects future revenue from out-licensing or commercialization of its drug candidates through standard pharmaceutical distribution channels. The company is led by CEO Floor Stam, PhD, and CSO Gerard Griffioen, PhD, and engages the scientific community through publications, conference presentations (including CTAD), and AI partnerships such as its 2025 collaboration with Unlearn on digital twin technology for clinical signal interpretation.

reMYND firmographics

Firmographics
Name
reMYND
Legal name
remynd NV
Website
https://remynd.com
Company type
Private
Founded year
2002
Operating status
Operating
Headcount range
11–50 employees
Short description
reMYND is a Belgian clinical-stage biotech developing first-in-class oral small molecule therapeutics for Alzheimer's and Huntington's disease using a proprietary septin modulation platform that restores calcium homeostasis in neurons.
Ownership category
akta.pro rank

reMYND industry classification

Industry
Product category
Neurodegenerative Disease Therapeutics
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Neurodegenerative therapeutics
  • Alzheimer's drug development
  • Huntington's disease treatment
  • Small molecule drugs
  • Clinical stage biotech

Where reMYND is headquartered

Location

Headquarters

HQ city
Heverlee
HQ country
Belgium
HQ region
Europe

Offices1 record

Markets served

reMYND business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Drug Development Programs: Developing proprietary small molecule therapeutics for neurodegenerative diseases (Alzheimer's and Huntington's disease) through clinical stages. Revenue will be generated upon regulatory approval and commercialization of drug candidates.
  2. CRO Services (Divested): Contract Research Organization services providing preclinical testing using proprietary mouse models for neurodegenerative diseases. This business unit was fully integrated into InnoSer in March 2025, ending reMYND's CRO operations.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

reMYND product offering

Product offering

Core offering

reMYND develops first-in-class oral small molecule drug candidates targeting neurodegenerative diseases, primarily Alzheimer's and Huntington's disease. The company's proprietary septin modulation platform restores calcium homeostasis in neurons by acting as a molecular glue to repair septin filament integrity. Lead candidates include REM392 (Alzheimer's, Phase 1), REM0046127/REM127 (Alzheimer's, Phase 2a completed), and REM949 (Huntington's, ready for CTA-enabling studies). Following the March 2025 divestiture of its CRO business to InnoSer, reMYND focuses exclusively on advancing these proprietary drug programs through clinical development.

Product overview

reMYND is a clinical-stage biotech company developing first-in-class oral treatments for neurodegenerative diseases, particularly Alzheimer's and Huntington's disease. The company's product portfolio centers on septin modulation technology—a novel mechanism targeting cytoskeletal proteins to restore calcium homeostasis in neurons. Lead programs include REM392 (second-generation Alzheimer's candidate in Phase 1), REM127 (first-generation Alzheimer's candidate completing Phase 2a), and REM949 (Huntington's disease candidate entering CTA-enabling studies). The company previously operated a CRO services business which was sold to InnoSer in March 2025, transitioning reMYND to a pure-play drug development organization. Research has been published in Science journal demonstrating the therapeutic potential of septin modulators.

Differentiator

Problem solved

Functional benefit

Products and services

  • REM392 Second-generation oral small molecule septin modulator for Alzheimer's disease. Restores calcium balance in neurons by targeting septin filaments disrupted by pathological tau. Designed with improved safety profile and pharmacokinetics compared to first-generation candidate REM127. Currently in Phase 1 clinical trials (initiated May 2025).
  • REM0046127 (REM127) First-generation small molecule drug candidate acting as molecular glue to restore septin filament integrity in neurons. Targeted mild-to-moderate Alzheimer's disease patients. Showed significant memory improvement and biomarker changes (p-tau181 reduction, EEG power increase, CSF dopamine increase) in Phase 2a trial. Program was terminated early due to off-target liver effects, leading to development of second-generation candidate REM392.
  • REM949 Lead compound for reMYND's Huntington's disease program. Highly potent, orally available small molecule with excellent brain permeability and promising non-clinical safety and pharmacokinetic properties. Targets neurotoxic effects of mutated huntingtin protein. Ready to enter CTA-enabling studies.
  • ReS19-T Compound Class Novel class of compounds identified through reMYND's Science publication that restore calcium homeostasis by targeting septins. Showed neuroprotective effects, reduced pathological protein accumulation, and improved memory function in multiple disease models of Alzheimer's. Forms the chemical foundation of reMYND's drug pipeline including REM392 and REM127.

Companies that use reMYND

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

reMYND technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

reMYND partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • InnoSercoreStrategic or Co-development Partner · 4 March 2025Strategic divestiture of reMYND's CRO business unit to InnoSer. The acquisition integrates reMYND's preclinical neuroscience models into InnoSer's neurology platform. This transition allows reMYND to focus exclusively on progressing its clinical drug programs while ensuring continuity of CRO services for global pharma and biotech clients.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

reMYND competitors and assessment

Company assessment

Direct peers

  • Cassava Sciences: Clinical-stage US biotech developing oral small molecules (simufilam) for Alzheimer's disease with a novel mechanism targeting altered protein folding/scaffolding — closely comparable to reMYND in modality (oral small molecule), indication (AD), and disease-modifying ambition.
  • Anavex Life Sciences: Clinical-stage biotech developing oral small molecules (blarcamesine) targeting sigma-1 receptor for Alzheimer's and other neurodegenerative diseases. Direct parallel to reMYND as an oral small-molecule CNS company pursuing disease modification.
  • Denali Therapeutics: Clinical-stage biotech developing small molecules and biologics for neurodegenerative diseases (including Parkinson's and ALS) using novel biology-driven approaches. Comparable as a CNS-focused drug developer with multiple programs and strong institutional backing.
  • AC Immune: Swiss clinical-stage biotech developing both small molecules and immunotherapies targeting misfolded proteins (tau, alpha-synuclein) in Alzheimer's and Parkinson's. Directly comparable to reMYND in targeting protein-misfolding biology in neurodegeneration.
  • Prothena Corporation: Clinical-stage biotech developing therapeutics for neurodegenerative diseases including Parkinson's, Alzheimer's and ATTR amyloidosis. Comparable as a protein-misfolding-focused CNS biotech with multiple clinical-stage programs.
  • Prilenia Therapeutics: Clinical-stage biotech developing pridopidine, an oral small molecule for Huntington's disease and ALS. Direct comparable to reMYND on the Huntington's program specifically, sharing oral small-molecule modality and CNS indication.
  • Wave Life Sciences: Clinical-stage biotech developing RNA-targeting therapies for Huntington's disease (and other CNS indications). Direct Huntington's competitor to reMYND's REM949, though differing in modality (antisense oligonucleotides vs. small molecule).
  • uniQure: Clinical-stage gene therapy company developing AMT-130 for Huntington's disease. Comparable to reMYND's REM949 as another late-preclinical/early-clinical HD therapeutic, though uniQure uses AAV gene therapy rather than a small molecule.

Broad incumbents

  • Biogen: Large biopharmaceutical company with leading Alzheimer's franchise (Leqembi, co-developed with Eisai) and a broader CNS/neurodegeneration pipeline. Comparable as the dominant commercial incumbent in AD that any disease-modifying small molecule like reMYND's would eventually compete against or partner with.
  • Eisai: Global pharmaceutical company with a major Alzheimer's franchise (Leqembi, Kisunla) and a deep neurodegenerative-disease pipeline. Broad incumbent comparable to reMYND's commercial landscape and a likely potential partner/acquirer for late-stage CNS assets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

reMYND social profiles

Digital presence

reMYND financial estimates

Financial estimate

Revenue estimate

Valuation estimate

reMYND leadership team

Management profile

Number of profiles

Profiles11 records

reMYND funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

reMYND M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about reMYND

What does reMYND do?

reMYND develops first-in-class oral small molecule drug candidates targeting neurodegenerative diseases, primarily Alzheimer's and Huntington's disease. The company's proprietary septin modulation platform restores calcium homeostasis in neurons by acting as a molecular glue to repair septin filament integrity. Lead candidates include REM392 (Alzheimer's, Phase 1), REM0046127/REM127 (Alzheimer's, Phase 2a completed), and REM949 (Huntington's, ready for CTA-enabling studies). Following the March 2025 divestiture of its CRO business to InnoSer, reMYND focuses exclusively on advancing these proprietary drug programs through clinical development.

Is reMYND a public or private company?

reMYND is a private company. It is classified as venture growth investor backed and is currently operating.

When was reMYND founded?

reMYND was founded in 2002. It employs 11 to 50 people.

Where is reMYND based?

reMYND is headquartered in Heverlee, Belgium, in the Europe region.

How does reMYND make money?

Two revenue lines are on record. Drug Development Programs are the primary driver. The others are CRO Services (Divested).

Who are reMYND's main competitors?

Direct peers on record are Cassava Sciences, Anavex Life Sciences, Denali Therapeutics, AC Immune, Prothena Corporation, Prilenia Therapeutics, Wave Life Sciences and uniQure. Broad incumbents are Biogen and Eisai.

Does reMYND have an API?

No public API is recorded for reMYND.

What industry is reMYND in?

reMYND's product category is Neurodegenerative Disease Therapeutics. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
European BiotechnologyRemynd receives €3.5M for Alzheimer’s trialRemynd received €3.5M from the Alzheimer’s Drug Discovery Foundation to advance its septin-modulating drug REM392 into patients with mild-to-moderate Alzheimer's. The funding supports a Phase 1b trial expected to start in early 2027, evaluating safety and cognition. The company is still seeking complementary financing for the study.RemyndRemynd secures €3.5 million investment from the Alzheimer's Drug Discovery Foundation to take its first-in-class septin modulator into Alzheimer's patientsRemynd announced a €3.5 million strategic investment from the Alzheimer's Drug Discovery Foundation for its lead candidate REM392, a first-in-class septin modulator for mild-to-moderate Alzheimer's disease. The funding will support a Phase 1b study in patients, expected to start in early 2027.YahooUnlearn and remynd Partner on Alzheimer’s Study to Strengthen Confidence in Early Clinical Signals Using Digital TwinsUnlearn and remynd announced results from a collaboration on remynd's Phase 2a trial of REM127 for Alzheimer's, presented at the 2025 Alzheimer's & Parkinson's Drug Development Summit. Unlearn's AI digital twin model, trained on over 26,000 participants, provided individualized comparators to interpret early signals. The results strengthened confidence in REM127 and support advancing a second-generation therapy.GlobeNewswirereMYND commences first-in-human trial of ReS19-T Alzheimer’s programreMYND NV commenced a first-in-human trial of its Alzheimer's candidate ReS19-T, a small molecule targeting cellular dysfunction. The phase I trial will assess safety, tolerability, and pharmacokinetics in healthy subjects. The company also appointed Staph Leavenworth Bakali as Chair and Hermann Russ as Chief Medical Officer.PR NewswireGlobal Type 1 Diabetes Market Report 2019: Pipeline Shows Shift Toward Disease-Modifying ApproachesResearch and Markets published a market report on the Type 1 Diabetes pipeline showing 243 products at active development stages across 189 companies, indicating a shift toward disease-modifying approaches including immunomodulatory therapies and beta-cell regeneration. The report highlights that while insulin remains the mainstay treatment, the pipeline is described as largely novel and diverse with considerable potential for beta-cell preservation. Key licensing and co-development deals include Novo Nordisk's agreement with reMYND and TetraGenetics' partnership with LifeArc.